COVID‐19‐related mortality in high‐risk individuals is substantial and current treatment options are limited. There is convincing evidence that the COVID‐19 vaccines reduce the severity of infection and prevent deaths. Three COVID‐19 vaccine...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=O111396863
2021년
-
0954-7894
1365-2222
SCI;SCIE;SCOPUS
학술저널
770-777 [※수록면이 p5 이하이면, Review, Columns, Editor's Note, Abstract 등일 경우가 있습니다.]
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
COVID‐19‐related mortality in high‐risk individuals is substantial and current treatment options are limited. There is convincing evidence that the COVID‐19 vaccines reduce the severity of infection and prevent deaths. Three COVID‐19 vaccine...
COVID‐19‐related mortality in high‐risk individuals is substantial and current treatment options are limited. There is convincing evidence that the COVID‐19 vaccines reduce the severity of infection and prevent deaths. Three COVID‐19 vaccines are approved in the United Kingdom with many more in development. There are limited data on the triggers and mechanisms of anaphylaxis to these vaccines. We review the potential allergenic compounds in the COVID‐19 vaccines and describe an innovative allergy support model for the vaccination hubs that allows most patients with severe allergy be immunized. Finally, we propose a practical algorithm for the investigations of anaphylaxis to these vaccines.
Second‐hand smoke and NFE2L2 genotype interaction increases paediatric asthma risk and severity